Browsing by UP Author "Takuva, Simbarashe G."

Browsing by UP Author "Takuva, Simbarashe G."

Sort by: Order: Results:

  • Allergic reactions to the Ad26.COV2.S vaccine in South Africa 
    Peter, Jonny; Day, Cascia; Takuva, Simbarashe G.; Takalani, Azwidihwi; Engelbrecht, Imke; Garrett, N.; Goga, Ameena Ebrahim; Louw, Vernon; Opie, Jessica; Jacobson, Barry; Sanne, Ian; Gail-Bekker, Linda; Gray, Glenda (Elsevier, 2022-02)
    BACKGROUND : The Janssen-Ad26.COV2.S vaccine is authorized for use in several countries, with more than 30 million doses administered. Mild and severe allergic adverse events following immunization (AEFI) have been ...
  • Clinical correlations to distinguish severe from milder forms of obstructive sleep apnoea syndrome using overnight oximetry for prioritising adenotonsillectomy in a limited-resource setting 
    Mlauzi, Raphael; McGuire, Jessica; Zampoli, Marco; Takuva, Simbarashe G.; Lawrenson, John; Singh, Yanita; Peer, Shazia (Elsevier, 2022-01)
    BACKGROUND : In resource-poor settings with limited surgical services, it is essential to identify and prioritise children with severe and very severe obstructive sleep apnoea syndrome (OSAS) to expedite surgery. McGill's ...
  • Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa 
    Miot, Jacqui; Leong, Trudy; Takuva, Simbarashe G.; Parrish, Andrew; Dawood, Halima (BMC, 2021-04)
    BACKGROUND: Cryptococcal meningitis in HIV-infected patients in sub-Saharan Africa accounts for three-quarters of the global cases and 135,000 deaths per annum. Current treatment includes the use of fluconazole and amphotericin ...
  • Durability of first line antiretroviral therapy : reasons and predictive factors for modifications in a Swaziland cohort 
    Takuva, Simbarashe G.; Louwagie, Goedele M.C.; Zuma, Khangelani; Okello, Velephi (OMICS Publishing, 2012-01-26)
    BACKGROUND: Optimizing initial antiretroviral therapy (ART) regimens is critical in improving the durability of treatment efficacy and patient prognosis. Reasons for and risk factors relating to the need for ART modifications ...
  • Eligibility for co-trimoxazole prophylaxis among adult HIV-infected patients in South Africa 
    Takuva, Simbarashe G.; Nabyoma, J.M.; Dawood, H.; Black, A.; Maartens, G.; Parrish, Andrew; Leong, T.D. (Health and Medical Publishing Group, 2019-04)
    Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) is a broad-spectrum antibiotic used to prevent opportunistic infections in patients with HIV infection. Primary prophylaxis with co-trimoxazole has been shown to ...
  • Incidence of cardiometabolic diseases in a Lesotho HIV cohort : evidence for policy decision-making 
    Sebilo, Motlalepula; Ledibane, Neo R.T.; Takuva, Simbarashe G. (AOSIS, 2021-06-28)
    BACKGROUND: Antiretroviral treatment (ART) has been associated with the development of certain cardiometabolic diseases (CMDs). The burden of CMDs amongst ART-experienced patients in sub-Saharan Africa was unknown. OBJECTIVE: ...
  • Infusion reactions after receiving the broadly neutralizing antibody VRC01 or placebo to reduce HIV-1 acquisition : results from the Phase 2b antibody-mediated prevention randomized trials 
    Takuva, Simbarashe G.; Karuna, Shelly T.; Juraska, Michal; Rudnicki, Erika; Edupuganti, Srilatha; Anderson, Maija; De la Grecca, Robert; Gaudinski, Martin R.; Sehurutshi, Alice; Orrell, Catherine; Naidoo, Logashvari; Valencia, Javier; Villela, Larissa M.; Walsh, Stephen R.; Andrew, Philip; Karg, Carissa; Randhawa, April; Hural, John; Gomez Lorenzo, Margarita M.; Burns, David N.; Ledgerwood, Julie; Mascola, John R.; Cohen, Myron; Corey, Lawrence; Mngadi, Kathy; Mgodi, Nyaradzo M. (Lippincott Williams and Wilkins, 2022-04)
    BACKGROUND : The antibody-mediated prevention (AMP) studies (HVTN 703/HPTN 081 and HVTN 704/HPTN 085) are harmonized phase 2b trials to assess HIV prevention efficacy and safety of intravenous infusion of anti-gp120 broadly ...
  • Safety evaluation of the single-dose Ad26. COV2.S vaccine among healthcare workers in the Sisonke study in South Africa : a phase 3b implementation trial 
    Takuva, Simbarashe G.; Takalani, Azwidhwi; Seocharan, shen; Yende-Zuma, Nonhlanhla; Reddy, Tarylee; Engelbrecht, Imke; Faesen, Mark; Khuto, Kentse; Whyte, Carmen J.; Bailey, Veronique; Trivella, Valentina; Peter, Jonathan; Opie, Jessica; Louw, Vernon; Rowji, Pradeep; Jacobson, Barry; Groenewald, Pamela; Dorrington, Rob E.; Laubscher, Ria; Bradshaw, Debbie; Moultrie, Harry; Fairall, Lara; Sanne, Ian; GailBekker, Linda; Gray, Glenda; Goga, Ameena Ebrahim; Garrett, Nigel (Public Library Science, 2022-06-21)
    Real-world evaluation of the safety profile of vaccines after licensure is crucial to accurately characterise safety beyond clinical trials, support continued use, and thereby improve public confidence. The Sisonke study ...
  • Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition 
    Corey, Lawrence; Gilbert, Peter B.; Juraska, Michal; Montefiori, David C.; Morris, Lynn; Karuna, Shelly T.; Edupuganti, Srilatha; Mgodi, Nyaradzo M.; DeCamp, Allan C.; Rudnicki, Erika; Huang, Yunda; Gonzales, Pedro; Cabello, Robinson; Orrell, Catherine; Lama, Javier R.; Laher, Fatima; Lazarus, Erica M.; Sanchez, Jorge; Frank, Ian; Hinojosa, Juan; Sobieszczyk, Magdalena E.; Marshall, Kyle E.; Mukwekwerere, Pamela G.; Makhema, Joseph; Baden, Lindsey R.; Mullins, James I.; Williamson, Carolyn; Hural, John; McElrath, Juliana; Bentley, Carter; Takuva, Simbarashe G.; Lorenzo, Margarita M. Gomez; Burns, David N.; Espy, Nicole; Randhawa, April K.; Kochar, Nidhi; Piwowar‑Manning, Estelle; Donnell, Deborah J.; Sista, Nirupama; Andrew, Philip; Kublin, James G.; Gray, Glenda; Ledgerwood, Julie E.; Mascola, John R.; Cohen, Myron S. (Massachusetts Medical Society, 2021-03-18)
    BACKGROUND : Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS : We enrolled at-risk cisgender men and transgender persons in ...
  • Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults 
    Gray, Glenda E.; Bekker, Linda‑Gail; Laher, Fatima; Malahleha, Mookho; Allen, Mary; Moodie, Zoe; Grunenberg, Nicole; Huang, Yunda; Grove, Doug; Prigmore, Brittany; Kee, Jia J.; Benkeser, David; Hural, John; Innes, Craig; Lazarus, Erica; Meintjes, Graeme; Naicker, Nivashnee; Kalonji, Dishiki; Nchabeleng, Maphoshane; Sebe, Modulakgotla; Singh, Nishanta; Kotze, Philip; Kassim, Sheetal; Dubula, Thozama; Naicker, Vimla; Brumskine, William; Ncayiya, Cleon N.; Ward, Amy M.; Garrett, Nigel; Kistnasami, Girisha; Gaffoor, Zakir; Selepe, Pearl; Makhoba, Philisiwe B.; Mathebula, Matsontso P.; Mda, Pamela; Adonis, Tania; Mapetla, Katlego S.; Modibedi, Bontle; Philip, Tricia; Kobane, Gladys; Bentley, Carter; Ramirez, Shelly; Takuva, Simbarashe G.; Jones, Megan; Sikhosana, Mpho; Atujuna, Millicent; Andrasik, Michele; Hejazi, Nima S.; Puren, Adrian; Wiesner, Lubbe; Phogat, Sanjay; Granados, Carlos Diaz; Koutsoukos, Marguerite; Van Der Meeren, Olivier; Barnett, Susan W.; Kanesa‑Thasan, Niranjan; Kublin, James G.; McElrath, Juliana; Gilbert, Peter B.; Janes, Holly; Corey, Lawrence (Massachusetts Medical Society, 2021-03-25)
    BACKGROUND : A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing ...
  • Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa : open label, single arm, phase 3B study (Sisonke study) 
    Jacobson, Barry Frank; Schapkaitz, Elise; Takalani, Azwi; Rowji, Pradeep; Louw, Vernon Johan; Opie, Jessica; Bekker, Linda‑Gail; Garrett, N.; Goga, Ameena Ebrahim; Reddy, Tarylee; Yende-Zuma, Nonhlanhla; Sanne, Ian; Seocharan, Ishen; Robinson, Michelle; Collie, Shirley; Khan, Amber; Takuva, S.; Gray, Glenda (BMJ Publishing, 2023-03)
    OBJECTIVE : To assess the rates of vascular thrombotic adverse events in the first 35 days after one dose of the Ad26.COV2.S vaccine (Janssen/ Johnson & Johnson) in healthcare workers in South Africa and to compare ...